Spyre Therapeutics (SYRE)
Market Price (12/27/2025): $32.94 | Market Cap: $2.0 BilSector: Health Care | Industry: Biotechnology
Spyre Therapeutics (SYRE)
Market Price (12/27/2025): $32.94Market Cap: $2.0 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24% | Trading close to highsDist 52W High is -5.0% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, Targeted Therapies, and Inflammatory Bowel Disease Therapeutics. | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13.87, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 19% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -224 Mil |
| Stock price has recently run up significantly6M Rtn6 month market price return is 116% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12% | ||
| Key risksSYRE key risks include [1] intense competition in its target therapeutic area of inflammatory bowel disease (IBD). |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, Targeted Therapies, and Inflammatory Bowel Disease Therapeutics. |
| Trading close to highsDist 52W High is -5.0% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13.87, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 19% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -224 Mil |
| Stock price has recently run up significantly6M Rtn6 month market price return is 116% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12% |
| Key risksSYRE key risks include [1] intense competition in its target therapeutic area of inflammatory bowel disease (IBD). |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Spyre Therapeutics (SYRE) experienced significant stock movement between August 31, 2025, and December 27, 2025, driven by several key developments:
<br><br>
<b>1. Positive Interim Phase 1 Results for SPY003.</b> On November 4, 2025, Spyre Therapeutics announced positive interim Phase 1 results for SPY003, their novel anti-IL-23 antibody. The trial demonstrated that SPY003 was well-tolerated and exhibited a half-life of approximately 85 days, supporting potential quarterly or twice-annual maintenance dosing. These results are anticipated to advance SPY003 into the SKYLINE Phase 2 platform trial.
<br><br>
<b>2. Favorable Interim Phase 1 Data for SPY002 and SPY072.</b> The company also reported positive interim Phase 1 results for SPY002 and SPY072 (anti-TL1A antibodies), as highlighted on November 4, 2025, and in earlier reports from June 2025. The data indicated favorable safety profiles, differentiated pharmacokinetic profiles supporting potential quarterly or biannual maintenance dosing, and complete suppression of free TL1A for up to 20 weeks. These outcomes are expected to lead to the advancement of SPY002 into the SKYLINE Phase 2 platform trial and SPY072 into the SKYWAY Phase 2 basket trial.
<br><br>
<b>3. Initiation of Key Phase 2 Clinical Trials.</b> Spyre Therapeutics initiated the Phase 2 SKYLINE-UC platform study in May 2025, which is designed to evaluate SPY001, SPY002, SPY003, and their combinations. Furthermore, the SKYWAY-RD basket study for SPY072 commenced in September 2025. These advancements indicate a robust pipeline progression, with the company expecting six Phase 2 proof-of-concept readouts in 2026.
<br><br>
<b>4. Strengthened Financial Position and Public Offering.</b> As of September 30, 2025, Spyre Therapeutics reported a pro forma cash position of $782.7 million, including $316 million in gross proceeds from a recent underwritten public offering. This strong financial standing is projected to provide a cash runway into the second half of 2028, enabling the continued advancement of its clinical programs.
<br><br>
<b>5. Positive Analyst Ratings and Price Target Increases.</b> In late 2025, Spyre Therapeutics received positive attention from financial analysts. Notably, in December 2025, Mizuho initiated coverage with an "Outperform" rating and a $53 price target, Citigroup initiated with a "Strong Buy" and a $64 price target, and Jones Trading upgraded its rating from "Hold" to "Strong Buy" with a $64 price target. The consensus among 11 Wall Street analysts is a "Buy" rating, with an average price target of $53.88, suggesting a significant potential upside.
Show moreStock Movement Drivers
Fundamental Drivers
The 102.8% change in SYRE stock from 9/26/2025 to 12/26/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| 9262025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 16.24 | 32.94 | 102.83% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 60.70 | 60.78 | -0.13% |
| Cumulative Contribution | � |
Market Drivers
9/26/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| SYRE | 102.8% | |
| Market (SPY) | 4.3% | 40.0% |
| Sector (XLV) | 15.2% | 19.7% |
Fundamental Drivers
The 116.4% change in SYRE stock from 6/27/2025 to 12/26/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| 6272025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 15.22 | 32.94 | 116.43% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 60.27 | 60.78 | -0.85% |
| Cumulative Contribution | � |
Market Drivers
6/27/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| SYRE | 116.4% | |
| Market (SPY) | 12.6% | 35.1% |
| Sector (XLV) | 17.0% | 34.8% |
Fundamental Drivers
The 36.9% change in SYRE stock from 12/26/2024 to 12/26/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| 12262024 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 24.07 | 32.94 | 36.85% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 51.25 | 60.78 | -18.58% |
| Cumulative Contribution | � |
Market Drivers
12/26/2024 to 12/26/2025| Return | Correlation | |
|---|---|---|
| SYRE | 36.9% | |
| Market (SPY) | 15.8% | 46.4% |
| Sector (XLV) | 13.3% | 42.4% |
Fundamental Drivers
The 239.3% change in SYRE stock from 12/27/2022 to 12/26/2025 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| 12272022 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 9.71 | 32.94 | 239.33% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 5.80 | 0.00 | -100.00% |
| P/S Multiple | 6.30 | ∞ | ∞% |
| Shares Outstanding (Mil) | 3.77 | 60.78 | -1513.01% |
| Cumulative Contribution | � |
Market Drivers
12/27/2023 to 12/26/2025| Return | Correlation | |
|---|---|---|
| SYRE | 63.1% | |
| Market (SPY) | 48.0% | 38.6% |
| Sector (XLV) | 18.2% | 34.9% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SYRE Return | 3% | -40% | -91% | 91% | 8% | 42% | -83% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| SYRE Win Rate | 50% | 42% | 42% | 50% | 67% | 50% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| SYRE Max Drawdown | -54% | -56% | -93% | -76% | -5% | -49% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | SYRE | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -98.8% | -25.4% |
| % Gain to Breakeven | 7954.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -58.6% | -33.9% |
| % Gain to Breakeven | 141.6% | 51.3% |
| Time to Breakeven | 65 days | 148 days |
| 2018 Correction | ||
| % Loss | -63.8% | -19.8% |
| % Gain to Breakeven | 175.9% | 24.7% |
| Time to Breakeven | 209 days | 120 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Spyre Therapeutics's stock fell -98.8% during the 2022 Inflation Shock from a high on 3/22/2021. A -98.8% loss requires a 7954.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-3 brief analogies for Spyre Therapeutics (SYRE):
- Like an early-stage Vertex Pharmaceuticals, but hyper-focused on developing highly effective, disease-modifying treatments for inflammatory bowel disease (IBD).
- Similar to Regeneron or Amgen, but specialized in creating next-generation antibody and oral therapies specifically for inflammatory bowel disease.
- A biotech aiming to develop the 'next-generation Humira or Entyvio' for conditions like Crohn's and ulcerative colitis, with a focus on improved efficacy and patient convenience.
AI Analysis | Feedback
- SPY001: A next-generation subcutaneous TL1A antibody being developed for the treatment of inflammatory bowel disease (IBD), designed for infrequent dosing.
- SPY002: An oral, gut-restricted α4β7 integrin inhibitor currently in preclinical development for the treatment of inflammatory bowel disease (IBD).
AI Analysis | Feedback
Spyre Therapeutics (symbol: SYRE) is a clinical-stage biotechnology company focused on the discovery and development of novel precision medicines.
As a clinical-stage company, Spyre Therapeutics does not currently have any commercial products on the market, nor does it generate revenue from product sales. Therefore, the company does not have "major customers" in the traditional sense, whether these be other companies or individual consumers.
The business model for companies at this stage involves advancing their drug candidates through preclinical and clinical development. Potential future monetization would typically come through licensing agreements, collaborations with larger pharmaceutical companies, or an outright acquisition once their pipeline assets show significant promise and progress towards regulatory approval.
AI Analysis | Feedback
null
AI Analysis | Feedback
Cameron Turtle, Chief Executive Officer
Cameron Turtle, D.Phil., is an experienced leader in building, financing, and shaping biopharma organizations from preclinical development to late-stage clinical trials and commercialization. Prior to joining Spyre Therapeutics, he served as Venture Partner at Foresite Labs and as Chief Strategy Officer of BridgeBio Pharma. Before that, he was the Chief Business Officer of Eidos Therapeutics, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for heart failure. Dr. Turtle was also a consultant at McKinsey & Company, working with pharmaceutical and medical device companies on M&A, growth strategy, clinical trial strategy, and sales force optimization. He has served as a Director for several other biotech companies, including CoA Therapeutics, Fortify Therapeutics, Dermecular Therapeutics, and Aspa Therapeutics, which suggests a pattern of involvement with companies that often receive private equity or venture capital backing. He currently serves on the board of directors of Oruka Therapeutics, Inc.
Scott Burrows, Chief Financial Officer
Scott Burrows, M.B.A., is a veteran of the biopharma industry with more than two decades of diverse experience and a proven track record in biopharmaceutical finance leadership roles spanning multiple public companies. Prior to Spyre, he served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc., where he helped lead Arcutis through a successful initial public offering (IPO), several further equity and debt financings, and the transition to a fully integrated commercial-stage company. The successful IPO and venture capital financings at Arcutis indicate experience with companies backed by significant private and public investment. Before Arcutis, Mr. Burrows was the head of international investor relations for Shire, plc. Earlier in his career, he spent 15 years at Amgen, Inc. in roles of increasing responsibility across financial planning and analysis, treasury, and investor relations. Mr. Burrows began his career at Arthur Andersen as a consultant.
Heidy King-Jones, Chief Legal Officer and Corporate Secretary
Heidy King-Jones was appointed as Chief Legal Officer and Corporate Secretary of Spyre Therapeutics effective September 1, 2023.
Sheldon Sloan, M.D., Chief Medical Officer
Sheldon Sloan, M.D., serves as the Chief Medical Officer of Spyre Therapeutics, a position he has held since 2024.
Brian Connolly, Chief Technical Officer
Brian Connolly is the Chief Technical Officer at Spyre Therapeutics.
AI Analysis | Feedback
The key risks to Spyre Therapeutics (SYRE) primarily stem from the inherent challenges of being a clinical-stage biotechnology company developing novel treatments.
- Regulatory Hurdles and Clinical Trial Risks: As a company without any approved products on the market, Spyre Therapeutics' success is contingent upon the successful outcome of its clinical trials and subsequent regulatory approvals. The process of obtaining regulatory approval for new drugs is complex and uncertain, and any delays or failures in clinical trials or regulatory processes could significantly impact the company's prospects and financial position.
- Lack of Revenue-Generating Products and High R&D Expenses: Spyre Therapeutics is currently a pre-revenue and loss-making company. It continues to invest heavily in research and development (R&D) to advance its product pipeline. These high R&D expenses, in the absence of revenue-generating products, could strain the company's financial resources and raise concerns about its cash burn and long-term financial viability.
- Intense Competition: The biotechnology industry, particularly in therapeutic areas such as inflammatory bowel disease (IBD) which Spyre Therapeutics is targeting, is highly competitive. The company faces competition from numerous established pharmaceutical companies and other biotech firms that are also developing similar therapeutic approaches. This intense competition could impact Spyre's ability to gain a dominant market position if its product candidates are approved.
AI Analysis | Feedback
There are two clear emerging threats for Spyre Therapeutics (SYRE):
- Pfizer's PF-07062119 (formerly RVT-3101) TL1A inhibitor: Pfizer's acquisition of Telavant in late 2023 for $7.1 billion, based on compelling Phase 2b data for this TL1A inhibitor in ulcerative colitis, represents a significant and advanced direct competitor to Spyre's lead candidate, SP-162. Given Pfizer's substantial investment and the strong clinical results reported for PF-07062119, this drug is significantly further along in development than SP-162 and, if successful in Phase 3, could establish a strong market position for TL1A inhibitors or capture substantial market share before Spyre's candidate reaches the market.
- Oral alpha4beta7 integrin inhibitors such as BridgeBio Pharma's BBT-401: While Spyre's SP-212 aims to differentiate through an extended half-life for infrequent dosing, the emergence of effective oral alpha4beta7 integrin inhibitors presents a threat. BridgeBio Pharma has reported positive Phase 2a data for its oral BBT-401 in Crohn's disease. The significant patient preference for oral administration over injections could make such a therapy highly disruptive and competitive, potentially impacting the market for injectable alpha4beta7 integrin inhibitors, regardless of their dosing frequency.
AI Analysis | Feedback
Spyre Therapeutics (SYRE) is a clinical-stage biotechnology company primarily focused on developing next-generation antibody treatments for inflammatory bowel disease (IBD) and other immune-mediated conditions. Their pipeline includes SPY001 (an anti-α4β7 integrin), SPY002 (an anti-TL1A antibody), and SPY003 (an anti-IL-23 antibody), along with several combination programs. The company is also exploring indications in rheumatoid arthritis (RA) with SPY002.
The addressable markets for the conditions Spyre Therapeutics is targeting are substantial:
- Inflammatory Bowel Disease (IBD): The global inflammatory bowel disease treatment market was valued at approximately USD 26.55 billion in 2023 and is projected to grow to USD 44.08 billion by 2032. Another estimate puts the global market size at USD 26.6 billion in 2024, expected to reach USD 47.3 billion in 2034. The North American market for IBD treatment was valued at USD 10.89 billion in 2023.
- Atopic Dermatitis: The global atopic dermatitis market size was valued at USD 6.14 billion in 2024 and is projected to reach around USD 12.97 billion by 2034. Other sources indicate the global atopic dermatitis drugs market size was estimated at USD 17.64 billion in 2024 and is projected to reach USD 29.88 billion by 2030. The global atopic dermatitis treatment market was also valued at USD 17.05 billion in 2024 and is expected to reach USD 32.04 billion by 2032.
- Asthma: The global asthma treatment market size is projected to grow from USD 28.55 billion in 2025 to USD 38.57 billion by 2034. Another report estimates the global asthma drugs market size at USD 26.49 billion in 2025 and forecasts it to reach around USD 41.04 billion by 2034. The global asthma therapeutics market was valued at around USD 25.7 billion in 2023.
AI Analysis | Feedback
Spyre Therapeutics (SYRE), a clinical-stage biotechnology company, anticipates several key drivers for future revenue growth over the next 2-3 years, primarily through the advancement and potential commercialization of its pipeline. As the company currently generates no meaningful revenue, these drivers are centered on successful clinical development and market expansion.
- Advancement of Lead Inflammatory Bowel Disease (IBD) Product Candidates: Spyre is progressing its pipeline of extended half-life antibodies, including SPY001 (targeting α4β7), SPY002 (targeting TL1A), and SPY003 (targeting IL-23), for the treatment of IBD. The company expects to deliver multiple Phase 2 proof-of-concept readouts in 2026 from its SKYLINE-UC platform trial in ulcerative colitis, which will assess these monotherapies and their combinations. Positive clinical data will be crucial for advancing these programs and unlocking future revenue potential.
- Successful Development and Market Penetration of Combination Therapies for IBD: Spyre is actively exploring rational combinations of its proprietary antibodies, such as SPY120, SPY130, and SPY230, in IBD. The goal is to achieve best-in-class efficacy with infrequent dosing, and a Phase 2 clinical trial evaluating these combinations is expected to be initiated. Demonstrating superior efficacy with these combinations could significantly differentiate Spyre's offerings and drive substantial market adoption.
- Expansion into New Therapeutic Areas, Particularly Rheumatic Diseases: Spyre is expanding its therapeutic focus beyond IBD into other immune-mediated diseases. Notably, the company initiated the Phase 2 SKYWAY-RD basket trial for SPY072 (an anti-TL1A antibody, also referred to as SPY002) in mid-2025, evaluating its potential in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), with topline results anticipated in 2026. Success in these large rheumatic disease markets would represent a significant expansion of potential revenue streams.
- Differentiation Through Extended Half-Life and Convenient Dosing: A core component of Spyre's strategy is developing antibodies with extended half-lives that allow for less frequent, subcutaneous dosing (e.g., quarterly or twice-annual). This improved patient convenience and adherence, coupled with the potential for superior efficacy, could provide a significant competitive advantage and drive market share upon the eventual commercial launch of its products.
AI Analysis | Feedback
Share Issuance
- In June 2023, in conjunction with its reverse merger with privately held Spyre Therapeutics, Aeglea BioTherapeutics issued approximately 13 million common shares and 365,000 shares of Series A preferred stock to former Spyre security holders.
- In October 2025, Spyre Therapeutics completed an underwritten public offering of 17,094,594 shares of common stock at $18.50 per share, generating approximately $316.2 million in gross proceeds.
Inbound Investments
- In June 2023, concurrent with the acquisition of privately held Spyre Therapeutics, Aeglea BioTherapeutics secured $210 million through a private placement (PIPE) from existing and new investors. This investment was anticipated to fund the company's operations into 2026.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to SYRE. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Spyre Therapeutics
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 55.55 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.0% |
| Rev Chg 3Y Avg | 2.6% |
| Rev Chg Q | 9.1% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | 17.7% |
| Op Mgn 3Y Avg | 16.4% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 20.6% |
| CFO/Rev 3Y Avg | 21.4% |
| FCF/Rev LTM | 18.1% |
| FCF/Rev 3Y Avg | 18.6% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Development of biopharmaceutical products for the treatment of patients with inflammatory bowel disease (IBD) | 1 | ||||
| Development fee and royalty | 2 | ||||
| License | 0 | ||||
| Total | 1 | 2 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Development of biopharmaceutical products for the treatment of patients with inflammatory bowel disease (IBD) | -339 | ||||
| Total | -339 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Single Segment | 110 | 162 | 83 | ||
| Total | 110 | 162 | 83 |
Price Behavior
| Market Price | $32.94 | |
| Market Cap ($ Bil) | 2.0 | |
| First Trading Date | 04/07/2016 | |
| Distance from 52W High | -5.0% | |
| 50 Days | 200 Days | |
| DMA Price | $27.48 | $18.86 |
| DMA Trend | up | up |
| Distance from DMA | 19.9% | 74.6% |
| 3M | 1YR | |
| Volatility | 75.3% | 69.5% |
| Downside Capture | 23.74 | 157.75 |
| Upside Capture | 361.45 | 166.66 |
| Correlation (SPY) | 40.7% | 46.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.48 | 2.46 | 2.16 | 2.33 | 1.68 | 1.66 |
| Up Beta | 3.64 | 3.24 | 3.62 | 2.44 | 1.48 | 0.90 |
| Down Beta | 4.88 | 5.06 | 4.05 | 3.13 | 2.00 | 1.97 |
| Up Capture | 388% | 423% | 303% | 360% | 225% | 867% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 12 | 25 | 39 | 70 | 130 | 379 |
| Down Capture | 84% | -34% | -36% | 134% | 135% | 109% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 8 | 17 | 24 | 55 | 118 | 366 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of SYRE With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| SYRE | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 38.1% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.3% |
| Annualized Volatility | 69.2% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | 0.75 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 42.2% | 46.1% | -2.2% | 6.9% | 32.9% | 26.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of SYRE With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| SYRE | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -31.7% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 178.5% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.7% |
| Sharpe Ratio | 0.27 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 10.5% | 10.0% | -2.1% | -6.3% | 5.2% | 1.9% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of SYRE With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| SYRE | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -18.7% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 138.0% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.26 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 14.7% | 15.8% | -0.7% | 0.3% | 11.3% | 3.6% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/4/2025 | -0.6% | 1.6% | 45.6% |
| 8/5/2025 | -5.4% | -5.8% | 0.7% |
| 5/8/2025 | 9.6% | 13.1% | 33.4% |
| 2/27/2025 | 7.2% | 11.6% | -2.3% |
| 11/7/2024 | 5.0% | -17.0% | -28.9% |
| 8/7/2024 | 2.9% | 0.7% | 13.9% |
| 5/9/2024 | 4.9% | 7.4% | 3.7% |
| 2/29/2024 | 9.0% | 41.6% | 34.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 11 | 15 |
| # Negative | 10 | 11 | 7 |
| Median Positive | 5.2% | 7.4% | 12.9% |
| Median Negative | -3.6% | -8.5% | -26.4% |
| Max Positive | 9.6% | 41.6% | 90.6% |
| Max Negative | -6.6% | -18.9% | -59.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11042025 | 10-Q 9/30/2025 |
| 6302025 | 8052025 | 10-Q 6/30/2025 |
| 3312025 | 5082025 | 10-Q 3/31/2025 |
| 12312024 | 2272025 | 10-K 12/31/2024 |
| 9302024 | 11072024 | 10-Q 9/30/2024 |
| 6302024 | 8072024 | 10-Q 6/30/2024 |
| 3312024 | 5092024 | 10-Q 3/31/2024 |
| 12312023 | 2292024 | 10-K 12/31/2023 |
| 9302023 | 11092023 | 10-Q 9/30/2023 |
| 6302023 | 8112023 | 10-Q 6/30/2023 |
| 3312023 | 5112023 | 10-Q 3/31/2023 |
| 12312022 | 3022023 | 10-K 12/31/2022 |
| 9302022 | 11032022 | 10-Q 9/30/2022 |
| 6302022 | 8042022 | 10-Q 6/30/2022 |
| 3312022 | 5052022 | 10-Q 3/31/2022 |
| 12312021 | 3082022 | 10-K 12/31/2021 |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.